Fri.Jan 05, 2018

article thumbnail

SpaceX Shifts Mystery Zuma Launch To Sunday Due To Extreme Weather

socalTECH

Hawthorne-based SpaceX says it has shifted its launch date for its mysterious "Zuma" government payload to January 7th, as extreme weather slowed preparations for launch in Florida. The launch--originally targeted for 5pm on Friday--is being made for a mysterious, U.S. government customer. No details on what the "Zuma" payload is or where it will be placed into space have been released.

SpaceX 124
article thumbnail

Silicon Beach Report Jan. 5: Snap’s Unusual Structure Led to Breakthroughs, But Also Problems

L.A. Business Journal

Snap’s unusual structure led to breakthroughs but also problems; Hulu nabs ‘Lost’ exclusive subscription streaming rights from Netflix; and SpaceX now targeting late January for Falcon Heavy launch.

Netflix 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Starry Extends Wireless Internet To LA

socalTECH

Starry , a Boston-based Internet Services Provider which uses it own, proprietary millimeter-wave, 5G band service to provide in-building gigabit broadband to customers, has launched into Los Angeles, as part of an expansion by the company to LA and Washington, DC. Starry said the beta launch is its first beyond Boston. Starry's service revolves around the "Starry Station", a Wi-Fi hub which connects to rooftop, millimeter-wave fixed wireless relay points.

Services 113
article thumbnail

The Booming Business of a Bomb Cyclone

Xconomy

Manufacturers of snow blowers and salt spreaders are seeing a major uptick this week.

109
109
article thumbnail

Can You Ask for Office Rent Relief? How to Manage Your Lease During COVID-19

Office leases are one of companies’ largest expenses, and if your whole team is working from home with no clear end in sight, you may be wondering what to do about your lease.

article thumbnail

Gossamer Bio Raises $100M

socalTECH

San Diego-based Gossamer Bio , a new biopharma startup founded by former executives of Receptos, has raised $100M in a Series A funding, the company said late Thursday evening. Gossamer said the funding included seed funding from Omega Funds, and a Series A co-led by ARCH Venture Partners and Omega Funds. Gossamer Bio was co-founded by Faheem Hasnain and Sheila Gujrathi, M.D., former executives at Receptos.

article thumbnail

How To Deliver Your Presentation In Half The Time You’d Allotted

Xconomy

Talking faster during a presentation is a bad idea. Here are a few better ones. It’s the day of your big presentation. You’ve spent the last few weeks fine-tuning every detail. You rehearsed last night, and you were flawless. You’ve never felt more prepared. Read Full Story.

Ideas 76

More Trending

article thumbnail

3 Common Personal Growth Opportunities That Most People Utterly Fail to Address

Xconomy

These failings are woven into the fabric of every single choice we make and everything we say.

100
100
article thumbnail

How To Validate Your Innovative Product As A Business

Startup Professionals Musings

In my experience with technical entrepreneurs, they work hard on creating an innovative and elegant solution, and assume that customers will flock to them (“if we build it, they will come”). The reality is that successful businesses these days require an equally elegant business model, with the right marketing, delivery channel, price, and target customers, to get real traction.

Product 55
article thumbnail

Assessing the Impact of Meltdown and Spectre: Companies Rush to Mitigate the Threat

Xconomy

As Intel is hit with class action lawsuits, enterprises are working quickly to assess the potential impact of the flaws.

Class 59
article thumbnail

Bio Roundup: Trump, Gottlieb, Gene Therapy Prices, IPO Hopes & More

Xconomy

Welcome to the new year. What will it bring? Hopefully a lot less hatred, greed, stupidity, and angst than 2017. But we’re not holding our breath. We emerged from the winter break pondering several of the year’s burning biopharma questions, including the volatility of the U.S. president and what it means for the biopharmaceutical business, a frequent target of his scattershot rants.

Pricing 55